184 related articles for article (PubMed ID: 18574005)
1. Orphan Drug Act passes quarter-century milestone in fight against rare diseases.
Lavine G
Am J Health Syst Pharm; 2008 Jul; 65(13):1205, 1210. PubMed ID: 18574005
[No Abstract] [Full Text] [Related]
2. The Orphan Drug Act Revisited.
Thomas S; Caplan A
JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
[No Abstract] [Full Text] [Related]
3. Orphan drugs and orphan tests in the USA.
Thoene JG
Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
[No Abstract] [Full Text] [Related]
4. Adopting orphan drugs--two dozen years of treating rare diseases.
Haffner ME
N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
[No Abstract] [Full Text] [Related]
5. The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases.
Haffner ME
Retina; 2005 Dec; 25(8 Suppl):S89-S90. PubMed ID: 16374359
[No Abstract] [Full Text] [Related]
6. Rare opportunities appear on the horizon to treat rare diseases.
Torres C
Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483
[No Abstract] [Full Text] [Related]
7. The routes to orphan drug designation--our recent experience at the FDA.
Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
[No Abstract] [Full Text] [Related]
8. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
9. The orphan drug backlash.
Maeder T
Sci Am; 2003 May; 288(5):80-7. PubMed ID: 12701333
[No Abstract] [Full Text] [Related]
10. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
Oo C; Rusch LM
J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
[No Abstract] [Full Text] [Related]
11. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
12. Rare-disease drugs to receive consideration on par with serious-disease drugs.
Thompson CA
Am J Health Syst Pharm; 2012 Nov; 69(22):1936-7. PubMed ID: 23135552
[No Abstract] [Full Text] [Related]
13. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA; Freeman SN; Imoisili MA; Coté TR
Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
[TBL] [Abstract][Full Text] [Related]
14. History of Orphan Drug Regulation-United States and Beyond.
Haffner ME
Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
[TBL] [Abstract][Full Text] [Related]
15. Adoption agents.
Wapner J
Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
[No Abstract] [Full Text] [Related]
16. Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
Kesselheim AS; Treasure CL; Joffe S
PLoS Med; 2017 Jan; 14(1):e1002190. PubMed ID: 28045970
[TBL] [Abstract][Full Text] [Related]
17. Should off-label drug use be off-the-table?
Rivkees SA
J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
[No Abstract] [Full Text] [Related]
18. Law and research could add up to profitable niche drugs.
Haefner B
Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
[No Abstract] [Full Text] [Related]
19. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
[TBL] [Abstract][Full Text] [Related]
20. Orphan drug regulations. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2013 Jun; 78(113):35117-35. PubMed ID: 23767079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]